36.79
price up icon167.18%   23.02
pre-market  Pre-market:  35.70   -1.09   -2.96%
loading
Celcuity Inc stock is traded at $36.79, with a volume of 27.54M. It is up +167.18% in the last 24 hours and up +193.38% over the past month. Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
See More
Previous Close:
$13.77
Open:
$45.96
24h Volume:
27.54M
Relative Volume:
44.97
Market Cap:
$1.39B
Revenue:
-
Net Income/Loss:
$-63.78M
P/E Ratio:
-13.73
EPS:
-2.68
Net Cash Flow:
$-53.91M
1W Performance:
+171.71%
1M Performance:
+193.38%
6M Performance:
+225.86%
1Y Performance:
+96.42%
1-Day Range:
Value
$35.00
$46.42
1-Week Range:
Value
$13.50
$46.42
52-Week Range:
Value
$7.575
$46.42

Celcuity Inc Stock (CELC) Company Profile

Name
Name
Celcuity Inc
Name
Phone
763-392-0767
Name
Address
16305 36TH AVENUE N, MINNEAPOLIS, MN
Name
Employee
87
Name
Twitter
Name
Next Earnings Date
2025-03-31
Name
Latest SEC Filings
Name
CELC's Discussions on Twitter

Compare CELC with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CELC
Celcuity Inc
36.79 521.42M 0 -63.78M -53.91M -2.68
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
460.83 120.60B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.63 60.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
324.79 42.87B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
595.19 36.23B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.51 31.54B 3.81B -644.79M -669.77M -6.24

Celcuity Inc Stock (CELC) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-01-25 Resumed Stifel Buy
Jul-22-24 Initiated Leerink Partners Outperform
Feb-22-24 Initiated Stifel Buy
Dec-08-23 Initiated H.C. Wainwright Buy
Oct-08-21 Initiated Canaccord Genuity Buy
Sep-07-21 Initiated Jefferies Buy
Jul-29-21 Initiated Cowen Outperform
Jul-27-21 Initiated Needham Buy
Jan-28-21 Reiterated H.C. Wainwright Buy
Dec-24-20 Reiterated H.C. Wainwright Buy
May-11-20 Resumed Craig Hallum Buy
Nov-20-18 Initiated H.C. Wainwright Buy
View All

Celcuity Inc Stock (CELC) Latest News

pulisher
07:48 AM

Celcuity stock price target raised to $50 from $27 at H.C. Wainwright - Investing.com

07:48 AM
pulisher
06:32 AM

Celcuity: What’s Happening With CELC Stock? - Forbes

06:32 AM
pulisher
05:10 AM

Will Celcuity Inc. continue its uptrendLow Drawdown Stock Screener with Analysis - Newser

05:10 AM
pulisher
04:35 AM

Celcuity eyes big market opportunity after breast cancer win - pharmaphorum

04:35 AM
pulisher
03:49 AM

Celcuity (NASDAQ:CELC) Given New $50.00 Price Target at HC Wainwright - Defense World

03:49 AM
pulisher
03:04 AM

Celcuity (NASDAQ:CELC) Given Buy Rating at Needham & Company LLC - Defense World

03:04 AM
pulisher
02:29 AM

Leerink Partners Issues Positive Forecast for Celcuity (NASDAQ:CELC) Stock Price - Defense World

02:29 AM
pulisher
01:03 AM

These 10 Stocks are Winning Big - Insider Monkey

01:03 AM
pulisher
12:48 PM

Celcuity announces $225M combined offerings; shares down - MSN

12:48 PM
pulisher
Jul 28, 2025

Celcuity Inc. Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock - GlobeNewswire

Jul 28, 2025
pulisher
Jul 28, 2025

Celcuity Preps For Potentially Huge Market After Phase III Gedatolisib Win - insights.citeline.com

Jul 28, 2025
pulisher
Jul 28, 2025

Celcuity rockets after positive trial results on breast cancer combo treatment - Sherwood News

Jul 28, 2025
pulisher
Jul 28, 2025

Celcuity announces $225 million in proposed public offerings - Investing.com

Jul 28, 2025
pulisher
Jul 28, 2025

Geda load of this: Celcuity rocks breast cancer phase III - BioWorld MedTech

Jul 28, 2025
pulisher
Jul 28, 2025

Celcuity shares skyrocket as breast cancer drug combo shows dramatic Phase 3 success - Invezz

Jul 28, 2025
pulisher
Jul 28, 2025

Celcuity Inc (CELC) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - investchronicle.com

Jul 28, 2025
pulisher
Jul 28, 2025

Celcuity price target raised to $60 from $28 at Leerink - TipRanks

Jul 28, 2025
pulisher
Jul 28, 2025

Celcuity stock rallies on Phase III breast cancer trial progress - Yahoo Finance

Jul 28, 2025
pulisher
Jul 28, 2025

Celcuity's triple cancer drug combo beats AstraZeneca in halting cancer progression, shows study - Mint

Jul 28, 2025
pulisher
Jul 28, 2025

Celcuity shares triple on late-stage results for breast cancer therapy - BioPharma Dive

Jul 28, 2025
pulisher
Jul 28, 2025

Celcuity rockets on new gedatolisib data - The Pharma Letter

Jul 28, 2025
pulisher
Jul 28, 2025

Celcuity to Present Updated Results for Treatment-Naïve Patients from Phase 1b Study of Gedatolisib at the 2023 ESMO Breast Cancer Annual Congress - ACCESS Newswire

Jul 28, 2025
pulisher
Jul 28, 2025

Celcuity Stock (NASDAQ: CELC) shares Skyrockets 210% on Breakthrough Breast Cancer Trial Results | Celcuity Stock Price - paginasiete.bo

Jul 28, 2025
pulisher
Jul 28, 2025

Biotech Stock Blasting Off After Late-Stage Trial Results - Schaeffer's Investment Research

Jul 28, 2025
pulisher
Jul 28, 2025

Alerus Financial Posts Better-Than-Expected Earnings, Joins Celcuity, SES AI, Abercrombie & Fitch And Other Big Stocks Moving Higher On Monday - 富途牛牛

Jul 28, 2025
pulisher
Jul 28, 2025

Celcuity Stock Triples on Positive Breast Cancer Treatment Study - Investopedia

Jul 28, 2025
pulisher
Jul 28, 2025

Celcuity's Breast Cancer Drug Trial Shows 210% Stock Surge - AInvest

Jul 28, 2025
pulisher
Jul 28, 2025

Celcuity Skyrockets 214%: Can This Biotech Breakout Sustain Momentum? - AInvest

Jul 28, 2025
pulisher
Jul 28, 2025

This Pharma Stock Rose 200% On Monday Morning And Retail Says Valuation Could Rise To $5B: Here’s Why - Stocktwits

Jul 28, 2025
pulisher
Jul 28, 2025

Celcuity Stock Skyrockets On Breakthrough Trial Data For Heavily Pretreated Breast Cancer - Benzinga

Jul 28, 2025
pulisher
Jul 28, 2025

Lawmakers demand crackdown on surge in counterfeit weight loss drugs - statnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Why Is Celcuity Stock (CELC) Up 210% Today? - TipRanks

Jul 28, 2025
pulisher
Jul 28, 2025

Why is CELC Skyrocketing in Premarket Trading Today? - Tokenist

Jul 28, 2025
pulisher
Jul 28, 2025

Celcuity stock soars after breast cancer drug shows 76% risk reduction - Fingerlakes1.com

Jul 28, 2025
pulisher
Jul 28, 2025

Celcuity Announces Positive Phase 3 Trial Results - TipRanks

Jul 28, 2025
pulisher
Jul 28, 2025

Celcuity's triple cancer drug combo tops AstraZeneca's in cutting progression in study - TradingView

Jul 28, 2025
pulisher
Jul 28, 2025

Celcuity's Gedatolisib: A Paradigm Shift in HR+/HER2- Advanced Breast Cancer Treatment - AInvest

Jul 28, 2025
pulisher
Jul 28, 2025

Relative strength of Celcuity Inc. in sector analysisFree Earnings Play Trade Plan With Alerts - Newser

Jul 28, 2025
pulisher
Jul 28, 2025

Celcuity Soars 112.27% on Positive Breast Cancer Trial Results - AInvest

Jul 28, 2025
pulisher
Jul 28, 2025

Celcuity stock soars after breakthrough breast cancer drug trial results By Investing.com - Investing.com Nigeria

Jul 28, 2025
pulisher
Jul 28, 2025

Celcuity stock soars after breakthrough breast cancer drug trial results - Investing.com

Jul 28, 2025
pulisher
Jul 28, 2025

Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival ('PFS”) Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial - The Manila Times

Jul 28, 2025
pulisher
Jul 28, 2025

Celcuity reports breakthrough breast cancer treatment results By Investing.com - Investing.com India

Jul 28, 2025
pulisher
Jul 28, 2025

Celcuity reports breakthrough breast cancer treatment results - Investing.com

Jul 28, 2025
pulisher
Jul 28, 2025

Breakthrough: New Breast Cancer Drug Quadruples Survival Time in Phase 3 Trial, Sets Historic Efficacy Record - Stock Titan

Jul 28, 2025
pulisher
Jul 28, 2025

Does Celcuity Inc. stock perform well during market downturnsFind market-beating stocks for your portfolio - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Celcuity's gedatolisib combo succeeds in pivotal breast cancer study - FirstWord Pharma

Jul 28, 2025
pulisher
Jul 28, 2025

Celcuity posts Phase 3 win in breast cancer, setting up challenge to Novartis and Roche - Endpoints News

Jul 28, 2025
pulisher
Jul 28, 2025

Why Celcuity Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - inkl

Jul 28, 2025
pulisher
Jul 28, 2025

Celcuity Stock Soars 10.24% Ahead of Breast Cancer Trial Results - AInvest

Jul 28, 2025
pulisher
Jul 28, 2025

Can Celcuity Inc. recover in the next quarter Fast Return Equity Forecast With Logic - Newser

Jul 28, 2025

Celcuity Inc Stock (CELC) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.09
price down icon 1.32%
$37.06
price up icon 1.06%
$101.75
price down icon 2.12%
$27.45
price down icon 4.26%
$112.79
price down icon 2.19%
biotechnology ONC
$294.51
price up icon 1.04%
Cap:     |  Volume (24h):